Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Its lead DMD product candidate is ezutromid, which is an orally administered small molecule. Its lead CDI product candidate is ridinilazole, which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid. Its DMD program is based on utrophin modulation. It has received an orphan drug designation to ezutromid for the treatment of DMD. It is also developing an earlier-stage pipeline of second and future generation utrophin modulators for the treatment of DMD.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: LON:SUMM
- CUSIP: N/A
- Web: www.summitplc.com/
Capitalization:- Market Cap: £117.63 million
- Outstanding Shares: 61,908,000
Average Prices:- 50 Day Moving Avg: GBX 179.63
- 200 Day Moving Avg: GBX 183.43
- 52 Week Range: GBX 88 - GBX 262
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: £4.05 million
- Price / Sales: 29.04
- Book Value: GBX (0.13) per share
- Price / Book: -14.62
Profitability:- EBIDTA: ($24,350,000.00)
- Net Margins: -275.52%
- Return on Assets: -55.76%
Misc:- Average Volume: 34,980 shs.
Frequently Asked Questions for Summit Therapeutics PLC (LON:SUMM)
What is Summit Therapeutics PLC's stock symbol?
Summit Therapeutics PLC trades on the London Stock Exchange (LON) under the ticker symbol "SUMM."
When will Summit Therapeutics PLC make its next earnings announcement?
Who are some of Summit Therapeutics PLC's key competitors?
Some companies that are related to Summit Therapeutics PLC include Chimerix (CMRX), Cempra (CEMP), Ovid Therapeutc (OVID), CymaBay Therapeutics (CBAY), ObsEva SA (OBSV), Urogen Pharma (URGN), Kindred Biosciences (KIN), uniQure N.V. (QURE), Foamix Pharmaceuticals (FOMX), Tocagen (TOCA), Kura Oncology (KURA), Cascadian Therapeutics (CASC), Zymeworks (ZYME), Madrigal Pharmaceuticals (MDGL), Faron Pharmaceuticals Oy (FARN), Gemphire Therapeutics (GEMP), Athersys (ATHX) and Spring Bank Pharmaceuticals (SBPH).
Who are Summit Therapeutics PLC's key executives?
Summit Therapeutics PLC's management team includes the folowing people:
- Glyn Edwards, Chief Executive Officer, Executive Director
- Erik Ostrowski, Chief Financial Officer
- David Roblin, Chief Operating Officer, President - Research and Development
- Ralf H. Rosskamp M.D., Chief Medical Officer
- Frank Murdoch Armstrong, Non-Executive Chairman of the Board
- Valerie L. Andrews, Non-Executive Director
- Stephen J. Davies, Non-Executive Director
- Barry J. Price Ph.D., Non-Executive Director
- David Wurzer CPA, Non-Executive Director
How do I buy Summit Therapeutics PLC stock?
Shares of Summit Therapeutics PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Summit Therapeutics PLC's stock price today?
One share of Summit Therapeutics PLC stock can currently be purchased for approximately GBX 190.
MarketBeat Community Rating for Summit Therapeutics PLC (LON SUMM)MarketBeat's community ratings are surveys of what our community members think about Summit Therapeutics PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Summit Therapeutics PLC (LON:SUMM) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Summit Therapeutics PLC (LON:SUMM)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 6/15/2017 | N+1 Singer | Reiterated Rating | corporate | |  |
(Data available from 7/24/2015 forward)
Earnings History for Summit Therapeutics PLC (LON:SUMM)Earnings History by Quarter for Summit Therapeutics PLC (LON SUMM)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 9/6/2017 | | | | | | | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Summit Therapeutics PLC (LON:SUMM)Current Year EPS Consensus Estimate: $-38.45 EPS
Dividend History for Summit Therapeutics PLC (LON:SUMM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Summit Therapeutics PLC (LON:SUMM)Insider Trades by Quarter for Summit Therapeutics PLC (LON:SUMM)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/17/2015 | Valerie Andrews | Insider | Buy | 10,500 | GBX 145 | £15,225 | |
(Data available from 1/1/2013 forward)
Headline Trends for Summit Therapeutics PLC (LON:SUMM)
Latest Headlines for Summit Therapeutics PLC (LON:SUMM)
| Source: |
|
| Date | Headline |
|---|
 | Sarepta (SRPT) Q2 Loss Narrows, Ups Exondys 51 Sales View - Nasdaq
www.nasdaq.com - July 21 at 7:31 AM |
 | Global Antibiotics Technologies, Markets, Competitors and Opportunities 2017-2022: The Quest for New Super Drugs
www.bizjournals.com - July 13 at 10:04 AM |
| Can Summit Therapeutics (SMMT) Run Higher on Strong Earnings ... - Nasdaq
www.nasdaq.com - July 4 at 3:40 PM |
 | Summit Therapeutics plc : Exercise of Share Options
finance.yahoo.com - June 29 at 7:06 AM |
| Summit Therapeutics Plc breached its 50 day moving average in a Bullish Manner : SUMM-GB : June 26, 2017
finance.yahoo.com - June 27 at 8:46 AM |
| Summit Therapeutics Plc :SUMM-GB: Earnings Analysis: Q1, 2018 By the Numbers : June 23, 2017
finance.yahoo.com - June 24 at 7:03 AM |
| Summit Presents Data from Phase 1 Clinical Programme of Ezutromid at the EPNS Congress
finance.yahoo.com - June 22 at 1:54 PM |
 | Summit Therapeutics Quarterly Loss Narrows On Milestone Revenue
www.morningstar.co.uk - June 15 at 10:13 PM |
 | BRIEF-Summit Therapeutics Plc Q1 loss £4.8 million
www.reuters.com - June 15 at 10:13 PM |
 | N+1 Singer Reiterates "corporate" Rating for Summit Therapeutics PLC (SUMM)
www.americanbankingnews.com - June 15 at 9:48 AM |
 | Summit Therapeutics plc : Notice of Results - London South East (registration) (blog)
www.lse.co.uk - June 15 at 1:33 AM |
| Summit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2017 on 14 June 2017 - Nasdaq
www.nasdaq.com - June 15 at 1:33 AM |
| BRIEF-Summit Therapeutics Plc Q1 loss £4.8 million - Reuters
www.reuters.com - June 15 at 1:33 AM |
| Summit Therapeutics Plc breached its 50 day moving average in a Bearish Manner : SUMM-GB : June 8, 2017
finance.yahoo.com - June 9 at 1:27 AM |
| Summit Announces Key Appointments to Strengthen Research and Development Team
finance.yahoo.com - May 23 at 9:03 AM |
| Summit Announces Key Appointments to Strengthen Research & Development Team
finance.yahoo.com - May 23 at 9:03 AM |
| Summit Therapeutics PLC's (SUMM) " Corporate" Rating Reiterated at N+1 Singer
www.americanbankingnews.com - May 16 at 8:28 AM |
| Summit Therapeutics Gets USD22 Million Milestone As Enrolment Complete
www.morningstar.co.uk - May 15 at 9:07 AM |
| Summit Completes Enrolment of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients with DMD
finance.yahoo.com - May 15 at 9:07 AM |
| Summit Therapeutics PLC (SUMM) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - May 6 at 5:02 AM |
| Summit Therapeutics plc: Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases
finance.yahoo.com - May 2 at 9:09 AM |
 | Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases With Data Showing Summit's Ridinilazole ... - GlobeNewswire (press release)
globenewswire.com - April 28 at 8:51 PM |
| Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases With Data Showing Summit’s Ridinilazole Achieved Statistical Superiority over Vancomycin in the Treatment of C. Difficile Infection
finance.yahoo.com - April 28 at 8:51 PM |
| Summit Therapeutics plc : Notice of AGM - GlobeNewswire (press release)
globenewswire.com - April 25 at 9:34 AM |
| Summit Therapeutics plc : Notice of AGM
finance.yahoo.com - April 25 at 9:34 AM |
| Summit Therapeutics plc : Grant of Share Options
finance.yahoo.com - April 12 at 12:49 PM |
| Summit Therapeutics Plc :SUMM-GB: Earnings Analysis: Q4, 2017 By the Numbers : April 4, 2017
finance.yahoo.com - April 7 at 12:51 PM |
| Summit Therapeutics plc : Change of Registered Office - GlobeNewswire (press release)
globenewswire.com - March 31 at 3:21 PM |
| Summit Therapeutics File US Annual Report on Form 20-F
finance.yahoo.com - March 31 at 3:21 PM |
| Summit Therapeutics Annual Loss Widens As It Progresses Pipeline
www.morningstar.co.uk - March 30 at 8:43 PM |
| Summit Therapeutics plc : Change of Registered Office
finance.yahoo.com - March 30 at 8:43 PM |
| N+1 Singer Reaffirms "corporate" Rating for Summit Therapeutics PLC (SUMM)
www.americanbankingnews.com - March 30 at 11:50 AM |
| Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017 and ... - GlobeNewswire (press release)
globenewswire.com - March 29 at 8:01 AM |
| Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017 and Operational Progress
finance.yahoo.com - March 29 at 8:01 AM |
| Summit Therapeutics Reports 4th Quarter and Year End Financial Results and Operational Progress
finance.yahoo.com - March 29 at 8:01 AM |
| Full Year 2017 Summit Therapeutics PLC Earnings Release - Before Market Open
biz.yahoo.com - March 29 at 8:01 AM |
| BRIEF-Summit to extend ongoing trial of Ezutromid in patients with Duchenne disorder
www.reuters.com - March 27 at 7:15 PM |
| Summit to Extend Ongoing PhaseOut DMD Clinical Trial of Ezutromid in Patients with DMD
finance.yahoo.com - March 27 at 8:57 AM |
| Summit Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference
finance.yahoo.com - March 15 at 8:20 AM |
| Summit Therapeutics Recognises 10th Annual Rare Disease Day
finance.yahoo.com - February 28 at 11:42 AM |
| Summit Therapeutics Recognises Tenth Annual Rare Disease Day
finance.yahoo.com - February 28 at 11:42 AM |
| SUMMIT THERAPEUTICS TO PARTICIPATE IN FEBRUARY INVESTOR CONFERENCES - London South East (registration) (blog)
www.lse.co.uk - February 3 at 6:03 AM |
 | Form 6-K Summit Therapeutics plc For: Feb 01 - StreetInsider.com
www.streetinsider.com - February 3 at 6:03 AM |
| Summit Therapeutics plc : 3rd Quarter Results - GlobeNewswire (press release)
globenewswire.com - December 16 at 5:07 AM |
| Q3 & 9M 2017 Summit Therapeutics PLC Earnings Release - Before Market Open
biz.yahoo.com - December 16 at 5:07 AM |
| Summit Therapeutics plc : Notice of Results
finance.yahoo.com - December 14 at 5:02 AM |
| Summit Therapeutics Presents Preclinical DMD Data at the 21st International Congress of the World Muscle Society
finance.yahoo.com - October 6 at 11:25 AM |
| Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy
finance.yahoo.com - October 4 at 11:04 AM |
| Summit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement With Sarepta Therapeutics for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy
finance.yahoo.com - October 4 at 11:03 AM |
 | BUZZ-Summit Therapeutics: Best day since 2009 on Sarepta deal
uk.finance.yahoo.com - October 4 at 11:03 AM |
Summit Therapeutics PLC (SUMM) Chart for Monday, July, 24, 2017
